Personalised Medicine Diagnostic Market Analysed in New Renub Research Study Now Available at MarketPublishers.com
18 Jun 2013 • by Natalie Aster
LONDON – Personalised medicine is gradually becoming the reality of future in the diagnostics industry globally. By technology, the personalised medicine diagnostic market is forecast to double its present size by the end of 2018. In this segment, point of care testing and molecular diagnostics hold the first and second positions, respectively, as of 2012. In terms of disease, the personalised medicine diagnostics market is expected to exceed USD 30bn by end-2018, with diabetes management test and cancer management test being the leading market segments.
HistoRx, A&G Pharmaceuticals Inc, 20/20 GeneSystems, Tethys Bioscience and Genomas Inc. are the leading players in the personalised medicine diagnostic field.
New market study “Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)” drawn up by Renub Research provides a comprehensive analysis of the emerging personalised medicine diagnostic market, segmenting it by technology, disease and geography. The study sheds light on the market dynamics, size, market share, key drivers and challenges, technological trends, leading companies, besides disclosing a potential for personalised medicine in clinical testing in the upcoming future. Furthermore, information on the clinical trial statement and major investors in the personalised diagnostics medicine market is also on hand in the report.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)
Published: June, 2013
Price: US$ 1,400.00
More new market studies by the publisher can be found at Renub Research page.